Secondary Logo

Journal Logo

Review Article

Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer

Miao, Jian-Long1; Liu, Rui-Juan1,; Zhou, Jin-Hua1; Meng, Shu-Hua2

Author Information
doi: 10.4103/0366-6999.194649
  • Free

Abstract

INTRODUCTION

Lung cancer is the most common cancer worldwide and the leading cause of cancer-related mortality despite improved diagnosis and therapy.[1] Nonsmall cell lung cancer (NSCLC) accounts for 75% of all lung cancers and includes two predominant subtypes, adenocarcinoma (ADC) and squamous cell carcinoma (SCC), which comprise 40% and 25% of NSCLCs, respectively. Due to the lack of specific symptoms, most lung cancer patients are in the mid or late stage of the disease when they were diagnosed. Although diagnostic approaches, treatment techniques, and surgical levels toward lung cancer treatment have been improved greatly in recent years, most lung cancer patients still have bad prognosis, with 5-year survival rates fluctuating around 15%.[2] It is of great significance in treatment selection and patient survival rate increase to look for factors relevant to lung cancer prognosis.

Fibroblast growth factor receptor 1 (FGFR1) has been identified as one of the emerging molecular targets for the treatment of SCC of the lung,[345] and several early-phase clinical trials of FGFR1 inhibitors are currently being undertaken in NSCLC.[678] Alterations of the FGFR gene have been recognized in many epithelial malignancies, including amplifications in gastric, breast, oral squamous cell, ovarian, and bladder carcinomas,[910] and more recently in squamous NSCLC. Previous studies of FGFR1 amplification in lung cancer have focused on SCC.[111213] This review summarizes the current knowledge of FGFR1 amplifications in the main subtypes of NSCLC. The next sections describe the prevalence and prognostic significance of FGFR1 amplification and report the clinical characteristics associated with FGFR1 amplification in NSCLC.

ROLE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN ONCOGENESIS

FGFR1 is a member of the Type 4 family of receptor tyrosine kinases, which consists of the closely related and highly conserved FGFRs 1–4. All these proteins are transmembrane receptors composed of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular part that contains the functionally relevant tyrosine kinase domain. Constitutive activation of FGFR1 occurs basically by three major mechanisms: gene amplification, translocation, or activating mutations. Compared to FGFR gene mutation and translocation, gene amplification of FGFR is most well studied. FGFR1 amplification is associated with poor prognosis[14] and one of the most frequent genetic changes in breast cancer.[1516] Amplification of FGFR1 has additionally been reported in SCC of the head and neck (17%) as well as of the esophagus (28.6%).[1718] Translocations of FGFR1 have originally been described in a myeloproliferative hematological disorder which has now been referred to as an “8p11 myeloproliferative syndrome characterized by FGFR1 translocation” by the current WHO classification system. Very recently, FGFR1 translocations have been additionally found in a subset of glioblastoma multiforme and in rhabdomyosarcoma.

The important advances achieved over the past decade through identifying oncogenic mutations in lung ADC have led to several efforts to screen for targetable oncogenes in SCC of the lung. FGFR1 amplification has been detected in SCC of the lung, with lower frequency in lung ADC.[1920] Lung cancer cells harboring FGFR1 amplification exhibit a highly tumorigenic phenotype, and FGFR1 regulates the stem cell-like phenotype of SCC of the lung.[21]

DETECTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 AMPLIFICATION BY FLUORESCENCE IN SITU HYBRIDIZATION

There are currently no validated antibody assays on the market, which could reliably detect FGFR1 expression levels quantitatively or semiquantitatively using paraffin-embedded tumor samples. Reliable FGFR1 fluorescence in situ hybridization (FISH) probes are now commercially available. In this review, we focused on the detection of FGFR1 amplification by FISH. In FISH, the FGFR1 gene locus is labeled with a green fluorochrome and the centromeric reference probe (CEN8) is labeled with an orange fluorochrome. Before hybridization, samples are cut into 5-µm sections, deparaffinized, and pretreated with the commercial pretreatment kit Vysis. Hybridization is performed overnight in a humidified chamber at 37°C. Next, slides are washed with Vysis washing solution and counterstained with 4’,6-diamidino-2-phenylindole.

We searched PubMed for English-language studies published between January 2010 and May 2016 using the terms “FGFR1” OR “fibroblast growth factor receptor 1” and “lung cancer” OR “lung carcinoma” or combinations thereof, and the references cited in the identified studies or reviews were also used to complete the search. The variability of FGFR1 amplification rates as determined by FISH is related to differences in the definition of a positive result and in interpretation of results. Table 1 shows the results of the literature search about FGFR1 amplification cutoff values and methods.

Table 1
Table 1:
FGFR1 amplification cutoff values and methods

FIBROBLAST GROWTH FACTOR RECEPTOR 1 AMPLIFICATION IN NONSMALL CELL LUNG CANCER EPIDEMIOLOGY

FGFR1 is one of the most frequently amplified genes in human cancer. Many researchers studied the prevalence of FGFR1 amplification in patients with NSCLC. Table 2 shows results of our literature search. From January 2010 to May 2016, 11 studies were identified and included in the final analysis. Statistics were not included for three of those studies due to alternative diagnoses focusing on SCC. In those three studies, FGFR1 amplification rates were 13.0% (34/262), 18.2% (22/121), and 16.0% (37/226).[192324] FGFR1 amplification was reported in 8.7–20.0% of NSCLC cases. FGFR1 amplification was significantly more frequent in SCCs (9.7–28.3%) than in ADCs (0–15.0%).

Table 2
Table 2:
Prevalence of FGFR1 amplification in nonsmall cell lung cancer (%)

The prevalence of FGFR1 amplification was 30.0% (3/10) in pleomorphic carcinomas[4] and 13.0% (3/23) in large cell carcinoma (LCC).[25] Russell et al.[27] confirmed that FGFR1 amplification was 16.7% (1/6) and 21.7% (5/23) in pleomorphic carcinomas and LCC, respectively.

ASSOCIATION BETWEEN FIBROBLAST GROWTH FACTOR RECEPTOR 1 AMPLIFICATION AND CLINICAL CHARACTERISTICS

The following clinical characteristics were extracted from each study: gender, smoking status, and disease stage. When referring to smoking status, we defined never smokers as adults who never smoked or smoked fewer than 100 cigarettes in their lifetime; former smokers were those who smoked at least 100 cigarettes but currently do not smoke; current smokers were people who smoked 100 cigarettes in their lifetime and currently smoke. Nonsmokers were defined as both former smokers and never smokers.[30]

Seven studies were identified and included in the final analysis [Table 3]. FGFR1 amplification was reported in 13.9–22.1% of male NSCLC patients and in 0–20.1% of female NSCLC patients. Cihoric et al.[25] and Russell et al.[27] found that FGFR1 amplification was significantly more frequent in male patients (14.8% and 17.1%, respectively) compared with female patients (5.9% and 8.5%, respectively).

Table 3
Table 3:
Rate of FGFR1 amplification according to clinical characteristics of patients with nonsmall cell lung cancer

FGFR1 amplification occurred in 13.3–29.0% of current smokers, 2.5–23.0% of former smokers, and 0–22.2% of never smokers. Kim et al.,[19] Craddock et al.,[23] and Russell et al.[27] reported that the frequency of FGFR1 amplification was significantly higher in current smokers than in former smokers and never smokers. As the smoking dosage increased, so did the rate of FGFR1 amplification. However, the remaining studies considered that there was no significant correlation between FGFR1-positive status and other clinicopathological features including smoking history.

FGFR1 amplification occurred in 9.3–24.1% of Stage I (IA and IB), 12.9–25.0% of Stage II (IIA and IIB), 8.2–19.5% of Stage III (IIIA and IIIB), and 0–12.5% of Stage IV NSCLC cases. Cihoric et al.[25] found a significant correlation between higher tumor stage and FGFR1 amplification rate. However, the remaining studies found contradictory results.

FIBROBLAST GROWTH FACTOR RECEPTOR 1 AMPLIFICATION AND PROGNOSIS

Seven studies were identified and included in the final analysis [Table 4]. Overall survival was 43.9–70.8 months in patients with FGFR1 amplification and 42.4–115.0 months in patients with no FGFR1 amplification; disease-free survival (DFS) was 22.5–58.5 months and 52.4–94.6 months, respectively. Two studies considered patients with FGFR1 amplification who died within the first 5 years, thus resulting in a significantly worse overall survival compared with patients with no FGFR1 amplification. Overall, the results were largely inconsistent across studies.

Table 4
Table 4:
Prognosis of FGFR1 amplification-positive and FGFR1 amplification-negative lung cancer patients

DISCUSSION

The ability to identify target oncogenic alterations in NSCLC has been a major advance in the management of patients. An important aspect of translating these molecular alterations into clinical practice is to develop assays that can quickly and reliably identify specific aberrations in clinical specimens. FGFR1 has recently emerged as a promising target in NSCLC. Our review reports that the prevalence of FGFR1 amplification was 8.7–20.0% in NSCLC and was significantly higher in SCC (9.7–28.3%) than in ADC (0–15.0%). The prevalence of FGFR1 amplification was 13.0–21.7% in LCCs and 16.7–30.0% in pleomorphic carcinomas.

There was no consistent relationship between FGFR1-positive status and clinical characteristics across studies. Most researchers reported that FGFR1 amplification was significantly more frequent in male patients compared with female patients and that the prevalence of smoking history was higher among patients with FGFR1 amplification than among those without. However, other researches reported no significant correlation between FGFR1-positive status and clinical features including gender, smoking history, and disease stage.

The prognostic significance of FGFR1 amplification in NSCLC was also inconsistent. Cihoric et al.[25] reported that FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Kim et al.[19] also reported that patients with FGFR1 amplification had significantly shorter overall survival and DFS than those without FGFR1 amplification. On the contrary, Russell et al.[27] compared overall survival and DFS between surgically radically treated patients with pure SCC and found no significant difference in overall survival in surgically radically treated patients stratified by stage and FGFR1 amplification status. However, Tran et al.[28] reported that FGFR1 amplification-positive patients show a tendency toward longer overall survival in univariate analysis. These inconsistent results may be caused by a variety of reasons: (1) The sample size in various series was too small to draw definitive conclusions. (2) The studies included patients with different disease stages. (3) The cutoff values were different across studies. Larger, multicenter studies will help clarify the prognostic significance of FGFR1 amplification in NSCLC.

FGFR1 has been discussed as a possible new therapeutic target. Therefore, FGFR1 amplification status should be evaluated prospectively in patients with lung SCC, LCC, and ADC. As patients with lung SCC have only limited options regarding systemic therapies, they might profit from a targeted therapy. Now, treatment with dovitinib demonstrated modest efficacy in patients with advanced SCC with FGFR1 amplification.[30] In contrast to targeted therapy development in lung ADC, trials targeting FGFR1 in lung SCC have been generally disappointing. Gene amplification or overexpression of this target may not be a sufficiently robust predictor of efficacy for FGFR1 inhibitors.[8] Therefore, the value of FGFR1 amplification in NSCLC has to be determined in further studies.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. . American Cancer Society. American Cancer Society Cancer Facts and Figures 2014 J Consum Health Internet. 2012;16:366–7 doi: 10.1080/15398285.2012.701177
2. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies Nat Rev Clin Oncol. 2011;8:135–41 doi: 10.1038/nrclinonc.2011.2141
3. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer PLoS One. 2011;6:e20351 doi: 10.1371/journal.pone.0020351
4. Sousa V, Reis D, Silva M, Alarcão AM, Ladeirinha AF, d'Aguiar MJ, et al Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma Virchows Arch. 2016;469:173–82 doi: 10.1007/s00428-016-1954-5182
5. Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, et al Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease PLoS One. 2014;9:e95303 doi: 10.1371/journal.pone.0095303
6. Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, et al Characterization of FGFR1 locus in sqNSCLC reveals a broad and heterogeneous amplicon PLoS One. 2016;11:e0149628 doi: 10.1371/journal.pone.0149628
7. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, et al Aphase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer Ann Oncol. 2011;22:1374–81 doi: 10.1093/annonc/mdq618
8. Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, et al Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study Cancer. 2016;122:3024–31 doi: 10.1002/cncr.30135
9. Turner N, Grose R. Fibroblast growth factor signalling: From development to cancer Nat Rev Cancer. 2010;10:116–29 doi: 10.1038/nrc2780
10. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer Biochem J. 2011;437:199–213 doi: 10.1042/BJ20101603
11. Göke F, Franzen A, Menon R, Goltz D, Kirsten R, Boehm D, et al Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors Chest. 2012;142:1020–6 doi: 10.1016/S0959-8049(12)71447-8
12. Jiang T, Gao G, Fan G, Li M, Zhou C. FGFR1 amplification in lung squamous cell carcinoma: A systematic review with meta-analysis Lung Cancer. 2015;87:1–7 doi: 10.1016/j.lungcan.2014.11.009
13. Wang Y, Gao W, Xu J, Chen X, Yang Y, Zhu Y, et al The role of FGFR1 gene amplification as a poor prognostic factor in squamous cell lung cancer: A meta-analysis of published data Biomed Res Int 2015. 2015 763080 doi: 10.1155/2015/763080
14. Chang J, Liu X, Wang S, Zhang Z, Wu Z, Zhang X, et al Prognostic value of FGFR gene amplification in patients with different types of cancer: A systematic review and meta-analysis PLoS One. 2014;9:e105524 doi: 10.1371/journal.pone.0105524
15. Khoo BL, Lee SC, Kumar P, Tan TZ, Warkiani ME, Ow SG, et al Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy Oncotarget. 2015;6:15578–93 doi: 10.18632/oncotarget.3903
16. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER) Lancet Oncol. 2014;15:267–74 doi: 10.1016/S1470-2045(13)70611-9
17. Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Mühling J, Hofele C, et al Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC) Oral Oncol. 2007;43:60–6 doi: 10.1016/j.oraloncology.2006.01.005
18. Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, Bass AJ, et al Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma Ann Thorac Surg. 2012;93:1101–6 doi: 10.1016/j.athoracsur.2012.01.064
19. Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, et al Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer J Clin Oncol. 2013;31:731–7 doi: 10.1200/JCO.2012.43.8622
20. Kohler LH, Mireskandari M, Knösel T, Altendorf-Hofmann A, Kunze A, Schmidt A, et al FGFR1 expression and gene copy numbers in human lung cancer Virchows Arch. 2012;461:49–57 doi: 10.1007/s00428-012-1250-y
21. Ji W, Yu Y, Li Z, Wang G, Li F, Xia W, et al FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the hedgehog pathway Oncotarget. 2016;7:15118–34 doi: 10.18632/oncotarget.7701
22. Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, et al Definition of a fluorescence in-situ hybridization score identifies high-and low-level FGFR1 amplification types in squamous cell lung cancer Mod Pathol. 2012;25:1473–80 doi: 10.1038/modpathol
    23. Craddock KJ, Ludkovski O, Sykes J, Shepherd FA, Tsao MS. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma J Thorac Oncol. 2013;8:1371–7 doi: 10.1097/JTO.0b013e3182a46fe9
    24. Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, et al FGFR1 amplification in squamous cell carcinoma of the lung J Thorac Oncol. 2012;7:1775–80 doi: 10.1097/JTO.0b013e31826aed28
    25. Cihoric N, Savic S, Schneider S, Ackermann I, Bichsel-Naef M, Schmid RA, et al Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer Br J Cancer. 2014;110:2914–22 doi: 10.1038/bjc.2014.229
    26. Seo AN, Jin Y, Lee HJ, Sun PL, Kim H, Jheon S, et al FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer Virchows Arch. 2014;465:547–58 doi: 10.1007/s00428-014-1634-2
      27. Russell PA, Yu Y, Young RJ, Conron M, Wainer Z, Alam N, et al Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH Mod Pathol. 2014;27:1621–31 doi: 10.1038/modpathol
      28. Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan BC, Kennedy CW, O'Toole SA, et al Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer Lung Cancer. 2013;81:462–7 doi: 10.1016/j.lungcan
      29. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer Sci Transl Med. 2010;2:357–62 doi: 10.1126/scitranslmed.3001451
        30. Schoenborn CA, Adams PF, Peregoy JA. Health behaviors of adults: United States, 2008-2010 Vital Health Stat. 2013;257:1–184

        Edited by: Qiang Shi

        Keywords:

        Fibroblast Growth Factor Receptor 1; Gene Amplification; Lung Cancer; Prognosis

        © 2016 Chinese Medical Association